Company Analysis
Sign in

MacroGenics, Inc. (MGNX)

Nasdaq: MGNX · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2003
Full chart Alerts Compare
Grade5.6
◀ Past 6.3● Present 5.5▶ Future 4.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

130 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to MacroGenics, Inc.’s names, not what it holds today.

Patents granted
130
130 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 6 in 2024 and 9 in 2023
Applications published
198
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Biotechnology15
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
MacroGenics, Inc. its own name
US, as the owner printed on each patent
130 granted
161 published
MacroGenics, Inc. its own name
named as the applicant on its applications, in US
0 granted
37 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,448,448Anti-PD-1 antibodies and uses thereofPharmaceuticalsMacroGenics, Inc.
Oct 7, 202512,435,155CD137 binding molecules and uses thereofBiotechnologyMacroGenics, Inc.
Jul 22, 202512,364,756Pharmaceutical compositions of a PD-1 antibody and use of the samePharmaceuticalsMacroGenics, Inc.
Dec 24, 202412,173,051Bispecific molecules comprising an HIV-1 envelope targeting armBiotechnologyMacroGenics, Inc.
Jul 30, 202412,049,501CD3-binding molecules capable of binding to human and non-human CD3PharmaceuticalsMacroGenics, Inc.
Jul 2, 202412,024,569HER2/neu-specific antibodies and methods of using samePharmaceuticalsMacroGenics, Inc.
Mar 26, 202411,942,149Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofPharmaceuticalsMacroGenics, Inc.
Jan 30, 202411,884,744Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereofPharmaceuticalsMacroGenics, Inc.
Jan 2, 202411,858,991LAG-3-binding molecules and methods of use thereofBiotechnologyMacroGenics, Inc.
Dec 12, 202311,840,571Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4BiotechnologyMacroGenics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0345422PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAMEPharmaceuticalsMacroGenics, Inc.
Oct 9, 20252025/0313628BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOFBiotechnologyMacroGenics, Inc.
Oct 2, 20252025/0304685COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOFPharmaceuticalsMacroGenics, Inc.
May 1, 20252025/0135022METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULEPharmaceuticalsMacroGenics, Inc.
Apr 17, 20252025/0122284CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3PharmaceuticalsMacroGenics, Inc.
Apr 10, 20252025/0115676ADAM9-Binding Molecules, and Methods of Use ThereofBiotechnologyMacroGenics, Inc.
Dec 12, 20242024/0409661Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses ThereofBiotechnologyMacroGenics, Inc.
Oct 10, 20242024/0336687PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAMEPharmaceuticalsMacroGenics, Inc.
Jul 11, 20242024/0233818BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOFPharmaceuticalsMacroGenics, Inc.
Jun 6, 20242024/0182559MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSPharmaceuticalsMacroGenics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 10 · Biotechnology 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MGNX · research, not advice